Cardiac Monitoring During Clinical Trials

MOONEN, Marie; Frere, Pol; Lancellotti, Patrizio; Jerusalem, Guy

doi:10.1016/B978-0-12-802509-3.00039-X

No full text

Contribution to collective works (Parts of books)

Cardiac Monitoring During Clinical Trials

MOONEN, Marie; Frere, Pol; Lancellotti, Patrizio et al.

2016 • In Anticancer Treatments and Cardiotoxicity 1st Edition Mechanisms, Diagnostic and Therapeutic Interventions

Peer reviewed

Permalink
https://hdl.handle.net/2268/225234

DOI
10.1016/B978-0-12-802509-3.00039-X

Files (0)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Adjuvant setting; Cardiac monitoring; Cardiac toxicity; Clinical trials; Heart failure; Trastuzumab

Abstract :

[en] The prognosis of breast cancer has greatly improved over time, particularly through the development of targeted therapy. Close cardiac monitoring during clinical trials investigating anticancer therapeutics is a field in cardiology that emerged 15 years ago. Indeed, anticancer agent-related cardiac dysfunction has been a nonanticipated adverse event in a phase 3 trial testing trastuzumab for metastatic breast cancer that overexpresses HER2. We propose hereby a description of the different strategies worked out to prevent cardiac dysfunction attributable to trastuzumab when it was evaluated in the adjuvant setting. This approach is still the fact of the studies designed since that and now, as a panel of cardiac toxicity has been associated with the development of these targeted therapies. © 2017 Elsevier Inc. All rights reserved.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

MOONEN, Marie ; Centre Hospitalier Universitaire de Liège - CHU > Service de cardiologie

Frere, Pol ; Université de Liège - ULiège > Interface Entreprises-Université

Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Imagerie cardiaque fonctionnelle par échographie

Jerusalem, Guy ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie

Language :

English

Title :

Cardiac Monitoring During Clinical Trials

Publication date :

2016

Main work title :

Anticancer Treatments and Cardiotoxicity 1st Edition Mechanisms, Diagnostic and Therapeutic Interventions

Publisher :

Elsevier Inc.

Pages :

387-399

Peer reviewed :

Peer reviewed

Commentary :

9780128025093

Available on ORBi :

since 14 June 2018

Statistics

Number of views

59 (2 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
Tan-Chiu E., Yothers G., Romond E., Geyer C.E., Ewer M., Keefe D., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23(31):7811-7819.
Suter T.M., Procter M., van Veldhuisen D.J., Muscholl M., Bergh J., Carlomagno C., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25(25):3859-3865.
Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353(16):1659-1672.
Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky B., Scherrer-Crosbie M., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovascu Imaging 2014, 15(10):1063-1093.
Perez E.A., Suman V.J., Davidson N.E., Kaufman P.A., Martino S., Dakhil S.R., et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004, 22(18):3700-3704.
Untch M., Muscholl M., Tjulandin S., Jonat W., Meerpohl H.G., Lichinitser M., et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 2010, 28(9):1473-1480.
Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(3):719-726.
Baselga J., Carbonell X., Castaneda-Soto N.J., Clemens M., Green M., Harvey V., et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23(10):2162-2171.
Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23(19):4265-4274.
Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
Perez E.A., Suman V.J., Davidson N.E., Sledge G.W., Kaufman P.A., Hudis C.A., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26(8):1231-1238.
Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354(8):809-820.
Joensuu H., Bono P., Kataja V., Alanko T., Kokko R., Asola R., et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009, 27(34):5685-5692.
Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365(14):1273-1283.
Burstein H.J., Piccart-Gebhart M.J., Perez E.A., Hortobagyi G.N., Wolmark N., Albain K.S., et al. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?. J Clin Oncol 2012, 30(18):2179-2182.
McArthur H.L., Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 2007, 357(1):94-95.
Wadhwa D., Fallah-Rad N., Grenier D., Krahn M., Fang T., Ahmadie R., et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009, 117(2):357-364.
Tarantini L., Gori S., Faggiano P., Pulignano G., Simoncini E., Tuccia F., et al. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol 2012, 23(12):3058-3063.
Pituskin E., Haykowsky M., Mackey J.R., Thompson R.B., Ezekowitz J., Koshman S., et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 2011, 11:318.
Lancellotti P., Anker S.D., Donal E., Edvardsen T., Popescu B.A., Farmakis D., et al. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)-EURObservational Research Program of the European Society of Cardiology. Eur Heart J Cardiovascu Imaging 2015, 16(5):466-470.